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Abstract: Parkinson’s disease (PD) is a complex neurological disorder classically characterized by 
impairments in motor system function associated with loss of dopaminergic neurons in the 
substantia nigra. After almost 200 years since the first description of PD by James Parkinson, 
unraveling the complexity of PD continues to evolve. It is now recognized that an interplay between 
genetic and environmental factors influences a diverse range of cellular processes, reflecting on 
other clinical features including non-motor symptoms. This has consequently highlighted the 
extensive value of early clinical diagnosis to reduce difficulties of later stage management of PD. 
Advancement in understanding of PD has made remarkable progress in introducing new tools and 
strategies such as stem cell therapy and deep brain stimulation. A link between alterations in gut 
microbiota and PD has also opened a new line. Evidence exists of a bidirectional pathway between 
the gastrointestinal tract and the central nervous system. Probiotics, prebiotics and synbiotics are 
being examined that might influence gut-brain axis by altering gut microbiota composition, enteric 
nervous system, and CNS. This review provides status on use of probiotics for PD. Limitations and 
future directions will also be addressed to promote further research considering use of probiotics 
for PD. 
Keywords: Parkinson’s disease; probiotics; prebiotics; synbiotics; gastrointestinal; gut; microbiota; 
dysbiosis 
 
1. Introduction 
Parkinson’s disease (PD) stands in second place after Alzheimer’s disease among common 
neurodegenerative disorders [1]. An overall incidence rate of 17 per 100,000 persons per year has 
been reported [2]. The onset of PD is usually at 65 years and older age, and it appears slightly more 
frequently in men than in women [2,3]. The aging of society around the globe is predicted to increase 
the population affected by PD and result in challenges for the provision of medical and socio-
economic care [4]. PD typically is known to be associated with the progressive loss of dopaminergic 
neurons in substantia nigra pars compacta [5]. Neurons in this region and other brain regions also 
develop abnormal intracellular deposits known as Lewy bodies that contain aggregated α-synuclein 
[6]. Relationship between degeneration of dopaminergic neurons and α-synuclein aggregation is 
unknown; however, an elegant study [7] has proposed a possible mechanism underlying 
dopaminergic cell death and α-synuclein aggregation [8].  
Motor impairment, characterized by resting tremor, muscle rigidity, and postural instability, has 
long been recognized as hallmarks of PD [9,10]. However, clinical features of PD include non-motor 
symptoms [11,12], including olfactory dysfunction [13,14], pain and sensory disturbances [15–17], 
and gastrointestinal (GI) dysfunction [18,19]. These symptoms have, in particular, been considered 
valuable for early diagnosis of PD [20] because they can occur years before initiation of motor 
symptoms [21]. A diverse range of biomarkers [22], from biological biomarkers (e.g., body fluids 
including cerebrospinal fluid, plasma, saliva, and recently tears [23–26]) to brain imaging biomarkers, 
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have been introduced over years to assist better diagnosis and treatment of PD [5,22]. Considering 
PD complexity, a combination of multimodal biomarkers would be ideal to enhance diagnostic 
accuracy and personalized medicine for PD [22]. 
Besides levodopa, which is the most used medication for treating motor symptoms of PD, other 
therapeutic agents such as monoamine oxidase type B inhibitors, amantadine, anticholinergics, β-
blockers, or dopamine agonists have also been used [27]. The rationale behind use of dopamine 
precursor and dopamine receptor agonists is to compensate for dopaminergic cell loss and to enhance 
dopaminergic load. It has been reported that levodopa was used by 85% of patients with PD in the 
USA (between 2001 and 2012), while dopamine agonists by 28% [28]. Levodopa, however, carries 
several side effects; it does not prevent dopaminergic neuron degeneration; it has no effects on non-
motor symptoms [29]; prolonged use of levodopa can lead to levodopa-resistance [29] and levodopa 
induced dyskinesia [30], and PD-associated GI dysfunction contributes to levodopa response [31,32]. 
As a consequence of recent advances in the understanding of PD, a number of new therapeutic 
approaches have been introduced [33], including genetic and disease-modifying approaches to 
reduce abnormal accumulation and aggregation of α-synuclein, mitochondrial dysfunction, 
dysfunction of lysosomal proteins, blockade of neuroinflammation, and enhancement of 
neurorestoration [34]. Besides novel compounds and repositioned drugs, new technologies such as 
cellular therapies, immunotherapies, and vaccines have been emerged together with non-
pharmacological approaches such as gene therapy, optogenetics, and deep brain stimulation, some 
of which already entered clinical phases of investigation [35]. A recent review has painted a bright 
future for PD within the next 20 years, where it can be slowed down, stopped, or reversed [36]. 
Recently, GI tract, enteric nervous system (ENS) [37], gut microbiota, and a cross talk of gut-
brain [19,38] have become a spot light as a potential mechanism underlying development of PD [39–
42]. A simplified illustration of communication between gut microbiota and brain can be seen in 
Figure 1.  
 
Figure 1. Communication between the gut microbiota and the brain [43] (reused with permission, 
license number: 4637571224608, Elsevier and Copyright Clearance Center). 
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GI dysfunction in PD was already highlighted by James Parkinson [44], and it is one of the most 
common non-motor symptoms with a prevalence of up to 80% [45]. GI dysfunction [18,46] appears 
as bloating, constipation, nausea, delayed gastric emptying, and prolonged intestinal transit time, 
leading to an incomplete defecation with a high negative impact on quality of life of patients with PD 
[45]. Constipation is highly prevalent (87%) and occurs before motor symptoms [47]. This may 
support the hypothesis that PD development and progression may occur at least in part with a 
contribution from the gut [39].  
Aggregated α-synuclein has been found in neurons outside the CNS [48], including the ENS. 
This finding led Braak et al. [49] to hypothesize that α-synuclein aggregates are formed outside the 
brain and travelled from peripheral tissues. Vagal nerve has been proposed to provide the path for 
this spread from the ENS to brain [50,51]. Later studies [52,53] have suggested that aggregation can 
be triggered by gut microbiota and this process not necessarily needs a pathogen or an environmental 
toxin [54] as it formerly was suggested [50]. Several lines of evidence support that gut-brain axis is 
influenced by the gut microbiota [55–57].  
Human GI tract hosts a diverse population of bacterial species, collectively called human gut 
microbiota, where a symbiosis exists between the host and bacteria [58–60]. Microbiome signatures 
in mouse, rat, non-human primate, and human faces have elegantly been studied and reported in 
2018 [61]. Data from this study provide important information about host-specific microbiome 
signatures and can be used as a starting reference for future studies for investigation of gut 
microbiome in health and disease. Interestingly, findings from study [61] show several common 
genera between the studied species that are highly valuable for translational studies from preclinical 
phases to clinic. Considering some limitations in this study, further investigation has been 
recommended by the authors, including higher control of dietary factors and inclusion of both sexes 
[61]. This is due to the fact that gut microbiota is influenced by several factors, including sex 
hormones, and diet [61,62]. The latter is influenced by factors such as geographical location and 
ethnicity, accessibility, and habits. Therefore, future studies considering these factors are valuable. 
Maintenance of a healthy microbiota is important for gut barrier integrity, immunity, function, 
metabolism [62,63], and the gut-brain axis [64]. A potential role of this axis in several CNS-associated 
disorders has been highlighted, including in multiple sclerosis [65] and PD [66,67]. Alterations found 
in gut microbiota, including number and composition of gut microbiota and microbial metabolites 
[68], have been considered as valuable signatures for early diagnosis of several neurodegenerative 
disorders [43], including PD. Excellent recent reviews are available on alterations of gut microbiota 
and potential molecular mechanisms of gut microbiota linked to pathogenesis of PD (see Figure 2 for 
a schematic illustration), where, based on the literature, targeting microbiota with a diverse range of 
interventions has also been proposed [19,40,41,46,69–78]. This review briefly summarizes current 
knowledge on disturbed gut microbiota in PD, followed by status of targeted interventions, with a 
particular focus on the use of probiotics in PD. 
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Figure 2. The role of gut microbiota in the pathogenesis of Parkinson’s disease. BBB, blood brain 
barrier; CRP, C-reactive protein; IL, interleukin; iNOS, inducible nitric oxide synthase; PD, 
Parkinson’s Disease; TNF, tumor necrosis factor [43] (reused with permission, license number: 
4637571224608, Elsevier and Copyright Clearance Center). 
2. Gut Dysbiosis in PD 
A range of PD-associated GI dysfunctions has been clinically identified, including weight loss, 
gastroparesis, constipation, and defecation dysfunction [79–81]. GI dysfunction is reported a 
potential contributor to PD pathogenesis. This notion is supported by pathophysiologic evidence that 
α-synuclein inclusions appear early in the ENS, then reach the brain by e.g., vagal nerves [50,82]. A 
sub-type of intestinal epithelial cells called enteroendocrine cells provide the signaling pathway 
through which the microbiome interacts with the CNS via the vagus nerve [83,84]. It is worth 
mentioning that α-synuclein aggregates are also seen in the ENS of normally aging individuals [85]; 
however, they are more prevalent in patients with PD [86]. In addition, direct evidence exists that 
injection of human α-synuclein fibrils into the gut tissue of healthy rodents is sufficient to induce 
aggregated α-synuclein pathology within the vagus nerve and brainstem [87]. In a genetic mice 
model of overexpression of α-synuclein, the presence of gut microbiota has been demonstrated 
necessary to promote pathological alterations and motor dysfunction similar to what is seen in PD 
[88]. Interestingly, in the same mouse strain, fecal transplants from patients with PD could result in 
impairment of motor function, showing that gut microbiota is actively involved in initiation of α-
synuclein proteinopathy in PD [88]. Once amyloids are produced by some members of the gut 
microbiota, they are released to extracellular space, and by neighboring cells including neurons, they 
can be internalized and form pathological aggregates of α-synuclein [89,90]. Clearance mechanisms 
such as the ubiquitin-proteasome system to degrade the misfolded protein are demonstrated failed 
in familial and idiopathic PD [91]. 
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Alterations in gut microbiota–dysbiosis-is evident in PD [74,92]. Table 1 presents altered gut 
microbiota in patients with PD [74]. 
Table 1. Altered gut microbiota compositions in PD patients [74] (reused with permission, license 
number: 4637580890170, Elsevier and Copyright Clearance Center). 
Altered Microbiota References 
Lactobacillus ↑, Clostridium coccoides ↓, Bacteroides fragilis ↓, 
[93] 
Prevotella (hydrogen sulfide producer) ↓ 
Ralstonia ↑, Blautia ↓, Coprococcus ↓, Faecalibacterium ↓, Roseburia ↓, [52] 
Enterobacteriaceae ↑, Prevotellaceae ↓ [92] 
Enterobacteriaceae ↑, Bifidobacterium ↑, Enterococcaceae ↓, 
[67] 
Lactobacillaceae ↓, Faecalibacterium prausnitzii ↓, Prevotellaceae ↓ 
Verrucomicrobiaceae ↑, Firmicutes ↑, Erysipelotrichaceae ↓, 
[94,95] 
Prevotellaceae ↓ 
Akkermansia ↑, Ruminococcaceae ↑, Lactobacillus↑, 
[66] 
Bifidobacterium ↑, Lachnospiraceae (SCFAs producer)↓ 
Escherichia-Shigella ↑, Streptococcus ↑, Proteus ↑, Enterococcus ↑, Blautia (butyrate 
produce) ↓, Faecalibacterium (butyrate produce) ↓, Ruminococcus ↓ 
[96] 
Clostridium IV ↑, Aquabacterium ↑, Holdemania ↑, Sphingomonas ↑, Clostridium XVIII 
↑, Butyricicoccus ↑, Anaerotruncus ↑, Lactobacillus ↓, Sediminibacterium ↓ 
[97] 
Patients with PD show an increased intestinal permeability correlated with intestinal α-
synuclein accumulation [53]. It has been proposed that increased intestinal permeability and the 
translocation of bacteria and inflammatory bacterial products might lead to inflammation and 
oxidative stress in GI and thereby initiating α-synuclein accumulation in the ENS [53]. In addition, 
gut-derived inflammatory products can promote the disruption of the blood brain barrier and thus 
facilitate dopaminergic loss occurring in the SN [98,99]. In line with this hypothesis, biopsies of 
colonic tissue obtained from patients with PD have been found with an increased expression of 
proinflammatory cytokines, including TNF-α, IFN-ɣ, IL-6, IL-1β, and increased activation of enteric 
glial cells [100]. 
Reduction of Prevotellaceae in fecal samples of patients with PD was reported in 2015 [92]. Lower 
Prevotellaceae diminishes the levels of health-promoting neuroactive short chain fatty acids (SCFA) 
and the capacity for biosynthesis of thiamine and folate [101] that is seen decreased in patients with 
PD [101,102]. Interestingly, Prevotella decrease might be related to lower synthesis of mucin, which is 
associated with increased gut permeability [53]. In addition, lower Prevotella and higher presence of 
Lactobacilliceae have been associated with lower concentrations of ghrelin. Ghrelin is a gut hormone 
that may be involved in the maintenance and protection of normal nigrostriatal dopamine function 
[103]. In line with this, impaired ghrelin secretion has been reported in patients with PD [104]. 
Interestingly, hydrogen sulfide secreted by Prevotella has been shown to exert a protective effect on 
dopaminergic neurons in rat and mouse models of PD [105].  
A study has reported that bacteria more commonly associated with anti-inflammatory 
properties, such as genus Blautia, Coprococcus, and Roseburia, are significantly reduced in fecal 
samples of patients with PD, along with a reduction in the genus Faecalibacterium and an increase in 
the genus Ralstonia in the GI mucosa of PD subjects, which potentially shifts the microbial balance 
within the colon to a more inflammatory phenotype [52].  
Immune factors in stool of patients with PD have been profiled recently [106], and findings from 
this study indicated that intestinal inflammation was present in 156 individuals with PD compared 
with 110 controls. Elevated levels of vascular endothelial growth factor receptor 1, IL-1α, and CXCL8 
were found in patients’ samples. Sex, body mass index, a history of smoking, and use of probiotics 
were found to strongly influence levels of stool analytes in this study [106]. Considering these factors 
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in analysis, results demonstrated that elevated levels of IL-1α, CXCL8, IL-1β and C-reactive protein 
in the patients’ samples and results were not dependent on subject age or disease duration [106]. This 
study shows that measurement of selective immune factors in stool can facilitate identification of 
individuals at risk [106].  
Stool samples of patients with PD compared with controls have also shown some alterations in 
fecal microbial composition and fecal SCFA concentrations [52,67]. SCFAs are important metabolic 
products of gut microbiota and exert central effects indirectly or directly on the ENS [107] and CNS 
[108]. Further metabolism of SCFAs results in Indican (indoxyl sulfate) that is eliminated in the urine, 
[109] and hence, urinary concentration of this substance can be considered a potential biomarker of 
gut dysbiosis [110].  
Small intestinal bacterial overgrowth (SIBO) is also evident in patients with PD [78,111,112], and 
is associated with bloating, flatulence, and malabsorption, and more severe motor fluctuations, based 
on evaluation by a questionnaire with Global Symptomatic Score. SIBO might cause changes in 
intestinal permeability and contribute to an increase in bacterial translocation and therefore induce 
an inflammatory response [113]. The results of recent studies about gut microbiol dysbiosis in 
patients with PD have been summarized in an excellent review from 2018 [74].  
A recent study showed significant differences in the gut phagobiota of patients with PD and a 
depletion of Lactococcus bacteria [114] in these patients that is associated with the regulation of gut 
permeability [115] and dopamine production [19], the two factors linked with the early gut signs of 
PD [116].  
Dysbiosis in gut microbiota is not limited to human studies and has also been reported in animal 
models of PD. For example, a recent study revealed that decreased phylum Firmicutes and order 
Clostridiales, along with increased phylum Proteobacteria, order Turicibacterales and Enterobacteriales, 
were found in fecal samples of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP)-induced PD 
mice, the increased abundance of Proteobacteria being consistent with observations in human subjects 
with PD [117]. Rotenone- treated mice have also exhibited fecal microbial dysbiosis characterized by 
an overall decrease in bacterial diversity and a significant change of microbiota composition, notably 
an increase in the Firmicutes/Bacteroidetes ratio after three weeks of rotenone treatment [118]. Sprague-
Dawley rats treated with rotenone have also been shown with elevated Bifidobacterium, Lactobacillus, 
Turicibacter, and Sutterella in the small intestine and colon and decreased Prevotella, S24-7 and 
Oscillospira [119]. The results of recent studies about gut microbiol dysbiosis in animal models of PD 
have been summarized in an excellent recent review [74].  
Taken together, evidence from human and animal studies demonstrates that alterations of gut 
microbiota exist in PD. Dysbiosis apparently results in differential production of a diverse range of 
substances in the gut that can influence gut-brain axis in PD. Various strategies have been used to 
study gut microbiota and how it might mediate PD pathology (e.g., germ-free, antibiotics, probiotics, 
fecal transplant, and infection). These strategies are summarized in a review paper from 2017 [76].  
It is not possible to determine if changes in the gut microbiota are a cause or a consequence of 
PD pathogenesis, but the net result is the neuronal loss following inflammatory cascades or oxidative 
reactions [54]. Overall, gut-brain axis is a bi-directional communication pathway, and in relation to 
PD, this notion has increasingly been supported [19]. Subsequently, this has led to targeting the gut-
brain axis in PD.  
3. Targeting Gut–Brain Axis in PD  
3.1. Antibiotics 
One of the potential therapeutic possibilities is the application of antibiotics. These agents have 
been long known to alter gut microbiota. A current interest has been formed around additional effects 
of antibiotics (e.g., anti-inflammatory, anti-aggregating, and antioxidant properties) in 
neurodegenerative diseases [120–122], besides their ability to rebalance the gut dysbiosis [123]. 
Antibiotics, therefore, are likely to affect the gut microbiota-brain axis. For example, minocycline, 
presented neuroprotective effect in MPTP animal model, where it could cross the blood brain barrier 
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and block dopamine loss [124]. It has been suggested that minocycline effect on gut-brain access is 
partly by modulating TLR4 [76]. Rifaximin has also been used for treatment of intestinal overgrowth, 
and this agent has also been reported to have an effect via TLR4 [125]. Further research is required to 
demonstrate that some antibiotics can act as alternative agents for PD.  
3.2. Fecal Microbiota Transplantation 
Fecal microbiota transplantation (FMT) is a technique, where feces (the entire gut microbiota) 
from a healthy donor is delivered into the GI tract of a patient by re-establishing a gut microbial 
community [126]. FMT is considered a more comprehensive approach to restore the gut microbiota, 
and it has been used for treatment of GI infection or other disorders. For example, FMT is highly 
effective for recurrent Clostridium difficile infection [127], to the point that it has been approved by the 
United States Federal Drug Administration (FDA) [128]. However, one study has highlighted that 
FMT might have an impact on patients’ immune system [129]. FMT has successfully been applied for 
treatment of other GI disorders including inflammatory bowel disease and irritable bowel syndrome 
[130]. Non-GI diseases have also been investigated to find whether FMT can be beneficial, and this 
area includes CNS disorders [131] including autism and multiple sclerosis [132].  
Animal studies in PD models have demonstrated that α-synuclein overexpressed mice receiving 
microbiota from patients with PD present higher physical impairments compared with transplants 
from healthy controls, highlighting that microbiome alterations can be a risk factor for PD [88]. 
Another study has presented that FMT protects MPTP-induced PD in mice by reducing the activation 
of microglia and astrocytes in the substantia nigra, and reducing expression of TLR4/TNF-α signaling 
pathway in gut and brain [117]. In this line, investigation of gut microbiota-miRNA interplay [133] 
has demonstrated that gut microbiota may affect host by producing miRNAs, and gut microbiota 
might be regulated by host-secreted miRNAs [134]. Gut microbiota modulates miRNA-associated 
mRNA expression patterns in the hippocampus of germ-free mice, where these transcriptional 
changes are sex-dependent [135]. This interesting study highlights a divergence between molecular 
pathways that control the gut-brain axis [135]. miRNAs control the TLR-signaling pathways, 
including regulation of TLR mRNA expression, receptor activation, binding to TLR or TLR-specific 
signaling, TLR-induced transcription factors, and cytokines [136]. Possible relationships between 
exosomes, miRNAs, and TLRs in the nervous systems have just started to be determined. However, 
hypothetically, miRNAs entering the cells via exosomes may tune the activation of TLRs [133], and 
that might be a useful strategy for modulation of the gut-brain axis in PD. 
These findings highlight the value of further investigation via translational studies to assess if 
FMT approach would be beneficial for PD. A number of issues need to be considered for the use of 
FMT, including ethical issues, selection and screening of appropriate donors, risk and benefit 
assessment, emotional and behavioral consequences, and long-term safety [133,134]. 
3.3. Dietary Interventions 
Dietary interventions [54] might influence the gut-brain axis by altering microbiota composition 
or by affecting neuronal functioning in the ENS and CNS [42,54,137]. Therefore, these interventions 
might provide opportunities to complement the traditional PD therapies [76]. Emerging evidence 
suggests that lifestyle factors can contribute to PD pathology. Smoking and coffee have been found 
associated with reduced risk of PD via their effects on gut microbiota [138]. There are number of 
excellent reviews on food-based treatments, dietary intervention, and probiotics for PD [54,139]. 
Below, the focus is on probiotics for PD. Table 2 presents the studies that have used microbial 
treatments for PD [72]. 
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Table 2. Comparison of studies using microbial treatment in Parkinson’s disease (PD) including a 
study with an animal model [72] (reused with permission, license number: 4637600311198, Springer 
Nature and Copyright Clearance Center). 
Element N  Type Treatment 
Duration 
Concentrations Disease 
Model 
Main Results References 
Probiotics 40 
Lactobacillus casei 
Shirota (in 
fermented milk) 
1× daily 
for 5 
weeks 
6.5 × 109 CFU 
PD 
patients 
Improvements in 
stool consistency and 
defecation habits 
[140] 
Probiotic 
mixture 
with 
prebiotic 
fiber 
80 
Streptococcus 
salivarius subsp. 
thermophilus, 
Enterococcus 
faecium, 
Lactobacillus 
rhamnosus GG, 
Lactobacillus 
acidophilus, 
Lactobacillus 
plantarum, 
Lactobacillus 
paracasei, 
Lactobacillus 
delbrueckii subsp. 
bulgaricus, and 
Bifidobacterium 
(fermented milk) 
1× daily 
for 4 
weeks 
2.5 × 1011 CFU 
PD 
patients 
Helped relieve 
constipation 
[141] 
Probiotics 20 
Lactobacillus 
acidophilus and 
Bifidobacterium 
infantis (tablets) 
2× daily 
for 12 
weeks 
120 mg/day 
Bacterial 
counts* 
PD 
patients 
Alleviated the 
symptoms of 
abdominal pain and 
bloating 
[142] 
Probiotics 30 
Lactobacillus 
acidophilus, 
Bifidobacterium 
bifidum, 
Lactobacillus reuteri, 
and Lactobacillus 
fermentum 
(capsules) 
1× daily 
for 12 
weeks 
8 × 109 CFU/day 
PD 
patients 
Decrease MDS-
UPDRS scores 
[143] 
FMT 15 
Fecal flora from 
normal C57BL/6 
mice 
1× daily 
for 7 days 
2 × 107 CFU 
MPTP 
murine 
PD 
model 
Show 
neuroprotective 
effects on MPTP-
treated PD mice by 
inhibiting glial cell 
activation and 
neuroinflammation 
[117] 
N, number of the intervention groups; FMT, fecal microbiota transplantation; CFU, colony-forming 
unit; PD, Parkinson’s disease; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MDS-UPDRS, 
the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; *CFU value was 
unavailable. 
4. Probiotics, Prebiotics, Synbiotics  
It has been over 17 years since the scientific definition of probiotics was introduced with 
guidelines to ensure appropriate use of the term [144]. An expert panel defined probiotics as, “live 
microorganisms which when administered in adequate amounts confer a health benefit on the host”[145]. In 
2014, a consensus panel made a small change replacing “which” with “that” [146]. Reid et al [144] 
have recently urged researchers to follow the precise definition and to stay consistent in order to help 
advance the development and validation of microbial therapies. Within this context, two other 
terminologies exist—prebiotics and synbiotics [147,148]. Prebiotics are mostly fibers that are non-
digestible food ingredients and beneficially affect the host’s health by selectively stimulating the 
growth and/or activity of some genera of microorganisms in the colon, generally lactobacilli and 
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bifidobacteria [147,148]. FAO/WHO defines prebiotics as “a non-viable food component that confer health 
benefit(s) on the host associated with modulation of the microbiota”. Synbiotics [149] are prebiotics 
combined with probiotics and this term is used for those products in which a prebiotic component 
selectively favors a probiotic microorganism [150].  
Pro, pre, and synbiotics field offers a huge potential in science and marketing [144,147]. The 
common benefit of probiotics on gut microbiota is by restoring microbiota and maintaining immune 
homeostasis [151]. Probiotics have been shown to enhance intestinal epithelial integrity, protect gut 
barrier disruption, regulate immune system in GI mucosa, and inhibit pathogenic bacterial growth 
[152–154]. Most commonly used probiotic species and strains are presented in a recent review [155] 
including several Lactobacillus spp., Bifidobacterium spp., Saccharomyces spp., and other coliform bacteria 
and their role in CNS disorders, obesity, diabetes, cancer, cardiovascular diseases, malignancy, liver 
disease, and multiple GI disorders to mention a few [155–157]. Probiotics have positive modulatory 
effects on brain function including reports showing normalization of anxiety [158,159] and 
depression-like behavior [160] through the gut-brain axis [139]. Long-term administration of the 
Lactobacillus rhamnosus strain in adult male BALB/c mice has been shown to reduce anxiety, 
depression, and stress responses, by modulation of central GABAAα2 but only in presence of intact 
vagus nerve. This finding highlights the importance of this communication path [161]. Our group has 
tested probiotic Lactobacillus rhamnosus PB01 on mechanical sensitivity and sperm kinematics in diet-
induced obese mice [162,163]. An experimental study applying autoimmune encephalomyelitis 
model in mice has demonstrated that a mixture of probiotic lactobacilli works via another path than 
vagus nerve, and that is through induction of transferable tolerogenic regulatory T cells in mesenteric 
lymph nodes, in the periphery and CNS, which is mediated through a mechanism associated to IL-
10 [164]. These examples show that effects and mechanisms underlying probiotics are diverse and 
broad spectrum and can be investigated through animal models of relevant diseases. Considering 
evidence in the literature in support of role of microbiota in various neurological disorders including 
PD [165], further attention and studies to investigate potential therapeutic use of probiotics in PD 
seem justified. Prebiotics and synbiotics have also been used but to a lesser extent. Probiotics are the 
most studied ones. Below, evidence available from these interventions for PD is provided.  
4.1. Probiotics for PD 
Preclinical or clinical evidence on the beneficial effects of probiotics in PD is still very limited. 
There are potentials to predict why probiotics, prebiotics, and synbiotics might be beneficial in PD 
[54]. Probiotics might be a powerful tool in order to alter PD-associated microbiota composition, 
improve GI function, and therefore reduce gut leakiness, bacterial translocation and the associated 
neuro-inflammation in the ENS. The first clinical study was conducted in 2011 and demonstrated that 
patients with PD suffering from chronic constipation receiving fermented milk containing 
Lactobacillus casei Shirota for five weeks improved stool consistency and reduced bloating and 
abdominal pain [140]. This study highlighted the value of the used probiotic for improvements in 
stool consistency and defecation habits in patients with PD. Besides dairy products, non-dairy 
products in form of tablet have been shown capable of reducing abdominal pain and bloating in 
patients with PD in a study from 2016 [142]. This study used probiotics (60 mg per-tablet of two lactic 
bacteria: Lactobacillus acidophilus and Bifidobacterium infantis) for 3 months.  
A recent randomized, double blind, placebo-controlled clinical study [143] (ClinicalTrials.gov 
Identifier IRCT2017082434497N4) has looked into the effects of a probiotic product in capsule format 
(containing Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus reuteri, and Lactobacillus 
fermentum) on clinical (e.g., movement) and biochemical profiles (including metabolic parameters) in 
PD [143]. Administration of probiotic for 12 weeks resulted in favorable impacts on MDS-UPDRS 
(Movement Disorders Society-Unified Parkinson’s Disease Rating Scale), high-sensitivity C-reactive 
protein (hs-CRP), blood glutathione (GSH), malondialdehyde (MDA), and insulin metabolism but 
did not affect other metabolic parameters. In addition, this study demonstrated that probiotic 
consumption reduced insulin levels and insulin resistance and enhanced insulin sensitivity 
compared with placebo [143]. One major limitation of this study is that fecal bacteria loads were not 
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determined prior and in response to the administered probiotics [143]. Authors have explained their 
findings in light of evidence in the literature for modulatory effects of probiotics on oxidative stress, 
insulin metabolism, and lipid profile [143].  
Recently, a UK-led clinical trial [166] is due to begin to test if a probiotic drink could help 
improve both the motor and non-motor symptoms of PD. Researchers in this team have indicated 
that they use Symprove (a clinical trial of the probiotic Symprove (K-1803)), which is an oral drinkable 
probiotic that claims to be able to deliver live bacteria to the lower gut. This is based on the fact that 
bacteria in many commercial probiotics are unlikely to reach the lower gut, as most types of them, 
due to acidic environment in the stomach, are being inactivated before their final destination. 
Symprove is a multi-strain liquid probiotic that aims to get beneficial bacteria through the acidic 
stomach intact. This funded trial has been designed as a randomized, double blind, placebo-
controlled trial and located in London. A total of 60 patients will be recruited and the intervention 
period is three months.  
Precise mechanisms underlying effects of probiotics in PD remain to be clarified. Most likely, 
effects are through multiple mechanisms. For example, improving gastrointestinal symptoms by 
probiotics can be a result of altering gut environment or inhibition of harmful gut bacteria [72]. For 
example, a lower abundance of Prevotella species in fecal samples from patients with PD has been 
reported [167] that can be corrected by probiotics. Another example is related to those patients with 
PD who are infected by Helicobacter pylori. It has been shown that these patients have lower 
absorption of L-DOPA [168]. Eradication of Helicobacter pylori by aid of some probiotics might then 
be useful in these patients. It has been shown that Probiotic Bifidobacterium bifidum CECT 7366 Strain 
affects Helicobacter pylori [169] and could be a potential option for future research in PD. Lactobacillus 
reuteri supplementation has also exerted anti Helicobacter pylori effects [170] and may offer some 
potentials for future investigation in PD.  
A lower count of Bifidobacterium species has also been found in the stool specimens from patients 
with progressive PD [171], proposing that probiotics might also be potentially useful in this case.  
Another potential mechanism is that probiotics can actually increase gut motility [172]. An in 
vitro organ bath study [173] has demonstrated that cell-free supernatants of Escherichia coli Nissle 
1917 can directly stimulate intestinal smooth muscle cells. Findings from this study therefore suggest 
a potential mechanism of probiotics to modulate human colonic motility [173].  
It has been shown that Lactobacillus reuteri accelerates gastric emptying and improves 
regurgitation in infants [174]. This might have an application for PD because delayed gastric 
emptying is common in patients with PD [175,176] and generally reduces absorption of PD 
medications including levodopa [32]. Identification of probiotics’ effects on gastric emptying and 
drug absorption in PD requires further investigation [72]. 
In general, consistency of stool has been found associated with gut microbiota richness and 
composition [177], and it seems justified to consider that probiotics could modulate constipation and 
or other GI motility issues [178]. 
Interestingly, there is in vitro evidence that probiotic bacterium Bacillus sp. JPJ can produce L-
DOPA from Ltyrosine, which is then converted to dopamine with the aid of DOPA decarboxylase 
[179]. This study might have some translational potential for future studies. However, one should 
consider that biochemical synthesis of some of endogenous substances such as L-DOPA might not be 
useful alone and needs further clarification on how to be translated in vivo and the impact on 
pharmacodynamics and pharmacokinetics must be determined.  
There is another in vitro evidence from 2019 [180] that presents effects of probiotic (a selection 
of probiotics microorganisms belonging to the lactobacillus and bifidobacterium genus) in peripheral 
blood mononuclear cells (PBMCs) isolated from patients with PD compared to healthy controls. 
Investigators in this study assessed release of the major pro and anti-inflammatory cytokines, in 
addition to production of reactive oxygen species (ROS). In patients with PD, L. salivarius LS01 and 
L. acidophilus significantly reduced proinflammatory and increased the anti-inflammatory cytokines. 
LA02 resulted in ROS downregulation, remarkably in the early stages of disease. These findings 
emphasize that results might be disease-stage dependent. In addition, anti-inflammatory and 
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antioxidant activities of LR06 and BS01 on PBMCs were different in cells obtained from males to 
females, which highlights a potential of sex-related response. Overall, findings from this study [180] 
pointed to promising results, but authors also acknowledged the limitations of the study including 
sample size and cross-sectional nature of the study design. Longitudinal in vivo studies to attempt 
reproduction of results have also been encouraged with an animal model of PD or direct evaluation 
of PD at clinic for both clinical and biological effects.  
Oxidative stress might be involved in apoptosis of dopaminergic neurons whether it is 
idiopathic or genetic cases of PD [123,181]. Probiotics that can promote production of antioxidant 
products, such as vitamins by gut microbiota, might offer beneficial effects for PD [76]. A number of 
vitamins have shown beneficial effects for patients with PD, including vitamin E, D3, Riboflavin, and 
vitamin B6 [76]. Healthy gut microbiota in humans produces vitamin K and most of the water-soluble 
B vitamins, such as biotin, cobalamin, folates, pantothenic acid, nicotinic acid, pyridoxine, riboflavin, 
and thiamine [182]. Probiotic strains such as lactobacilli and bifidobacteria are capable of producing 
potential antioxidants, vitamins, and bioactive molecules [183,184], potentially limiting free radicals 
load and exerting beneficial effects for disorders that are associated with oxidative stress including 
PD.  
Animal models of PD have shown that infiltrating CD4+ lymphocytes [185] and peripheral 
monocytes [186] into CNS contributes to neurodegeneration. Therefore, if probiotics exert immune 
regulatory effects, they might offer potentials for PD. It has been reported that oral Pediococcus 
acidilactici R037 could be effective in experimental autoimmune encephalomyelitis (EAE) [187]. 
Lactobacillus plantarum A7 and Bifidobacterium animalis have also been demonstrated effective in 
attenuating EAE progression in another study using this model [188]. In patients, probiotics have 
shown to modulate the microbiome and immunity in multiple sclerosis [189]. This study has tested 
oral probiotic containing Lactobacillus, Bifidobacterium, and Streptococcus twice-daily for two months 
and shown that the intervention resulted in anti-inflammatory response in the peripheral immune 
system characterized by decreased frequency of inflammatory monocytes, decreased CD80 on 
monocytes, and decreased human leukocyte antigen D on dendritic cells [189]. Examples presented 
above are not directly linked to PD but are based on the rationale that common mechanisms 
underlying disease progression have been shown to contribute in neurodegeneration caused by 
autoimmune responses and hence from this point of view might be useful to consider potential links 
to PD. There are currently no reports available to show if probiotics could exert an immune 
modulatory effect in PD; hence, this line is open for further investigation. 
In addition, influence of SCFA on central microglia in PD and potential role of probiotics in this 
regard require further investigation [190]. There is evidence in literature to encourage more studies 
in this line. For example, in infants (three months age) with high risk of eczema, probiotic 
supplementation (Bifidobacterium bifidum W23, Bifidobacterium animalis subsp. lactis W52 and 
Lactococcus lactis W58, Ecologic(®)Panda) could modulate fecal SCFA [191]. Probiotic 
supplementation in this study resulted in higher levels of lactate and SCFAs and lower levels of 
lactose and succinate [191]. Another study in 2–5 year old children has also found beneficial effects 
of probiotic supplementation (Lactobacillus paracasei Lpc-37 or Bifidobacterium lactis HN019) for nine 
months on total lactobacilli, bifidobacteria and SCFAs [192], that could reduce risk for diarrhea and 
fever during the rainy season.  
Evidence on immunomodulatory role of probiotics in gut lipopolysaccharide (LPS) and its 
relation to PD is not known and can offer another line of investigation. Few studies are available to 
encourage further research. An in vitro study [193] has demonstrated that specific probiotics, in this 
case B. longum subsp. infantis, might decrease colonic LPS and consequently reduce the 
proinflammatory milieu [193]. An in vivo study has also shown that Malaysian LAB-fermented cow’s 
milk (CM-LAB), consisting of several Lactobacilli, could reduce LPS-induced neuroinflammation in 
mice and reverse memory deficits in this LPS-induced model [194].  
Potential TLRs signaling has also been proposed that can be modulated by probiotics in relation 
to PD [133]. For example, L. rhamnosus (JB-1), Lactobacillus casei Shirota, and Lactobacillus reuteri by 
potential modulation of TLR1, TLR2, and TLR6 [140,161,195,196],  
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It remains to be investigated whether and how probiotics can influence dementia and cognitive 
impairments in PD. There are some experimental and clinical data available for improvement of 
theses impairments for Alzheimer’s disease. For example, in a murine model of Alzheimer’s disease, 
Bifidobacterium breve strain A1 could reverse cognitive dysfunction [197]. Another mice model of 
Alzheimer’s disease also showed promising results in response to SLAB51 probiotic formulation, 
where the treated group showed reduction of cognitive decline compared with control [198]. Clinical 
data from a randomized, double blind, and controlled trial in 2016 show that 12 weeks of 
consumption of a mixed-species probiotic product in form of a milk, consisting of Lactobacillus 
acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum could improve 
mental state in patients with Alzheimer’s disease assessed by mini-mental state examination (MMSE) 
scores [199].  
Use of probiotics for improvement in depression and anxiety in patients with PD is also very 
limited. In a germ-free mice model [200], administration of Lactobacillus plantarum PS128 was used to 
investigate emotional behaviors in response of gut-brain axis modulation. Results from this study 
presented an improvement in anxiety-like behaviors but not depressive behaviors, following the 
intervention [200]. This study proposes that behavioral responses (anxiety or depression) to 
probiotics might be different. Probiotics have also been tested for depression in humans and could 
show some promising results in irritable bowel syndrome [201] and in major depressive disorders 
[202]. Bifidobacterium longum NCC3001 reduced depression scores in irritable bowel syndrome [201], 
and Lactobacillus helveticus and Bifidobacterium longum in major depressive disorder [202]. According 
to these studies, probiotics might be useful for reducing depression or anxiety in patients with PD, 
but literature lacks any evidence so far.  
4.2. Prebiotics for PD 
A range of prebiotics exists [147] that originate from different sources including soybeans, raw 
oats, unrefined wheat and barley, yacon, non-digestible carbohydrates, and non-digestible 
oligosaccharides [147]. A low-molecular-weight polysaccharide from agar and alginate of seaweed 
Gelidium CC2253 F, Ulvan from green algae-Ulvarigida, ß-glucans from Pleurotus sp. (pleuran) 
mushrooms, inulin-type fructans from roots of traditional Chinese medicine Morindaofficinalis or 
Indian mulberry, oligosaccharide from white and red-flesh pitayas (dragonfruit), and oligosaccharide 
Yacon root have also been mentioned in the literature [147]. One must consider the prebiotic 
classification criteria and which one of these can fulfill the criteria to be included as prebiotics 
[54,203]. 
Prebiotic fibers have been shown to have beneficial effects on immune function, bowel motility, 
and constipation [54,204–209] that might be very relevant for inflammation and GI-related symptoms 
in PD. Moreover, prebiotics have been shown to increase the levels of brain-derived neurotrophic 
factor (BDNF) in the dentate gyrus of the hippocampus in rats [210]. BDNF signaling is critical for 
neuronal protection, survival, and plasticity [211]; therefore, supplementation might have 
implications on brain neuroprotection. In addition, fecal microbial community of PD has shown a 
lower abundance of SCFA butyrate-producing bacteria [52,67] that could be corrected by the use of 
prebiotic fibers. 
4.3. Synbiotics for PD 
Synbiotics exert beneficial effects on immune function, dysbiosis, and bowel function that 
collectively are relevant for PD. A clinical study has demonstrated that probiotic Lactobacillus 
salivarius decreased inflammatory markers in healthy subjects, and when it was combined with 
prebiotics, the effect was pronounced [212]. Another study has revealed that females with functional 
constipation that treated with a synbiotics yogurt, consisted of Bifidobacterium animalis combined with 
prebiotics, showed an increase in bowel movement, stool quantity, and quality compared to controls 
[213].  
A study from 2016 (ClinicalTrials.gov identifier: NCT02459717) was based on a randomized, 
double blind, placebo-controlled trial in patients with PD with Rome III-confirmed constipation, in 
Int. J. Mol. Sci. 2019, 20, 4121 13 of 26 
 
which daily intake of a fermented milk, containing multiple probiotic strains and prebiotic fiber, was 
tested for four weeks. The primary efficacy endpoint was the increase in the number of complete 
bowel movements (CBMs) per week and the findings presented constipation relief in patients 
compared to placebo [141]. Constipation severely affects the overall quality of life in patients with 
PD [214], and effective treatment options can offer great values at clinic. However, a link between 
dairy product consumption and increased risk of PD has been mentioned in the literature [215,216]. 
Potential adverse effects associated with the long-term use of fermented dairy products combined 
with probiotics are still unknown. In addition, we still do not know whether constipation relief 
following probiotics can also slow down progression of PD and to what extent. There is however a 
two-year follow-up study that examined gut dysbiosis correlation with progression of PD [171]. 
Therefore, future studies are encouraged to consider factors such as disease onset or progression into 
account while reporting quality of e.g., life of affected patients.  
The study by khalighi et al [217] showed that in patients with SIBO when treatment with 
antibiotics was followed by synbiotic supplementation containing Bacillus coagulans and prebiotics, a 
better response was obtained compared with antibiotics alone. The combined regimen also 
significantly decreased abdominal pain, flatulence, and diarrhea [217]. Since SIBO is prevalent in PD 
[78], and motor dysfunction is worse in these patients positive for SIBO [112], synbiotics have a 
potential to be considered for PD.  
Collectively, these studies listed above present potentials for probiotics, prebiotics, and 
synbiotics for PD.  
5. Conclusions and Future Perspectives 
Accumulating evidence supports contribution of the gut-brain bidirectional pathway [19] and 
role of dysbiosis [74] in PD. A healthy gut microbiota can potentially decrease risk of developing 
several human disorders, most likely also PD [68]. α-synuclein deposition in PD might start in the 
ENS and propagate to CNS by trans-synaptic cell-to-cell transmission. Induction of a 
proinflammatory environment under dysbiosis conditions could also signal to brain through 
systemic pathways and dysfunctional blood brain barrier [54]. Consequently, an imbalance in host 
immune system might be responsible, at least in part, for motor and non-motor symptoms of PD. 
This new insight into PD pathogenesis has stimulated investigation of novel and early biomarkers 
and novel therapeutic strategies. Among options for correction of gut dysbiosis, probiotics, 
prebiotics, and synbiotics [148] have been investigated for effects on GI dysfunction, levodopa 
uptake, side effects of PD medications, and initiation or progression of neurodegenerative process. 
Findings from both preclinical and clinical data that were presented in this review have now proven 
that gut microbiota can directly or indirectly modify brain neurochemistry via various mechanisms 
including neural, immune, and endocrine processes. Based on this scientific rationale, further steps 
are expected in this field. This also shows that treatment of neurodegenerative disorders including 
PD may require a combination of therapeutic options, and those need to be individually adapted to 
disease process and progression for an optimal outcome [36,218]. 
Future studies on PD should account for the gut-brain axis and the manipulation of gut 
microbiota and microbial metabolites [68]. Even though recent evidence shows that gut microbiota 
can regulate CNS immune response, microglia, neurophysiological processes (e.g., 
neurotransmission), behavior, and blood brain barrier integrity, further understanding of 
mechanisms underlying these effects is highly encouraged. Cause-effect relationship between 
dysbiosis of gut microbiota and PD has been shown in particular in preclinical settings, and it has 
been shown that potentially a far more complex link exists beyond the unidirectional cause-effect 
relationship [68] and the fact that α-synuclein is now proposed to be a “bystander” contributing to 
multiple neurodegenerative processes, including PD [218]. Maintaining healthy gut microbiota may 
face limitations and challenges but the potential is currently promising.  
As presented here, probiotics, prebiotics, and synbiotics have demonstrated potential for PD; 
but when data are limited or mixed or weakness exists in quality of evidence, these interventions 
should not be exaggerated. We still need to find effects of exogenously administered probiotics on 
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residential bacterial populations and intestinal microenvironments in patients with PD. There is also 
a need for more consistency in design of studies for probiotic strain types, strain combinations, 
duration of intervention, and application dosages. It is also important to define the “effect” of 
prebiotics, probiotics, or synbiotics clearly in study design to facilitate further interpretation of data 
and finding mechanistic information in relation to pathogenesis of PD. For example, inflammatory 
status and specific measures of inflammatory factors need to clearly facilitate our understanding in 
relation to impact on PD. Both preclinical and clinical studies would benefit from these factors 
because they can directly or indirectly influence trials’ outcomes.  
In future trials, composition of gut microbiota under optimal controlled conditions and after 
interventions needs to be assessed, and that might help individualized therapy in PD. Personalized 
probiotic approaches [219] might yield more reliable results, considering high variability in gut 
microbiota and the fact that effects of probiotics show high variability. To overcome some of those 
variabilities, use of genetically modified probiotics and new techniques for delivering these efficiently 
with high site specificity have been suggested [220]. A detailed analysis is crucial in determining 
which microbial communities are present as disease biomarkers in PD and also what are the potential 
responses to, e.g., probiotic intervention (considering most effective probiotics, dosage and duration) 
[192].  
Identification of changes in PD microbiota that can regulate brain function remains a challenge. 
Multi-omics approaches can be employed including metagenomics, metaproteomics, and 
metabolomics [72]. An integrative analysis of multi-omics has not been done so far to investigate gut 
microbiota and their metabolites in patients before and after probiotic intervention. One study has 
identified microbiome signatures in several species including humans [61]. Programs such as the NIH 
Human Microbiome Project (HMP) could provide resources, methods, and discoveries on human 
microbiome and health-related outcomes [221]. This project has been carried out over ten years with 
two phases completed for three conditions of pregnancy and preterm birth, inflammatory bowel 
disease, and factors influencing individuals with prediabetes [222]. Genomic blueprint of human gut 
microbiota [223] is also available based on a recent study on 92,143 metagenome-assembled genomes 
obtained from 11,850 gut microbiomes [223]. These powerful tools are supposed to facilitate future 
research.  
It is also important to consider objective measures in addition to other self-report questionnaires 
like Rome III criteria for future trials of probiotics in PD. For example, colonic transit time is a valid 
indicator, and has been used to objectively evaluate the severity of constipation among patients with 
PD [224]. This concept of objective biomarkers can exploit to non-GI markers and those in PNS or 
CNS. For example, it has been proposed [218] that using wearable, non-invasive body worn devices 
can be useful to collect information on movement and daily activities in relation to disease 
progression and drug effects [225,226].  
In future, correlational analysis to draw a link between two categories of findings, subjective and 
objective measures, are highly encouraged, for example, correlation between the stage of PD disease 
and outcome of probiotic intervention. At least, future studies are expected to report these parameters 
and factors that are taken into consideration for design and analysis.  
Another open question is whether persistent exposure to probiotics may lead to colonization of 
long-term residence in GI of patients with PD, or microbiota would return to its original after 
stopping probiotic intervention [72]. This would clarify whether continuous use of probiotics is 
required or can it be sufficient for a temporary period [72]. A longitudinal study, in which biomarkers 
and clinical findings can be collected before and after probiotics intervention, would likely provide 
important findings. Literature shows studies with single-strain probiotic and multispecies probiotics. 
Each strategy might have pros and cons, but one point is that identification of single strain makes 
some of the findings explanation more straightforward than those with multiple strains [72].  
Last, but not least, there have been few studies addressing concerns about safety of probiotics 
[227], and future studies are encouraged to take safety biomarkers into account to be included in 
study design and reported beside efficacy measures.  
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